Overexpression of KMT9α is associated with poor outcome in cholangiocarcinoma patients

• DOI: 10.1007/s00432-025-06214-w
• Publication Date: 2025-05-13T01:54:53Z
• Authors: Maximilian N. Kin...; Eric Metzger; Rebecca Schulz; Katrin Bankov; Anna Ramos-Triguero; Falko Schulze; Steffen Gretser; Nada Abedin; Armin Wiegering; Stefan Zeuzem; Dirk Walter; Henning Reis; Roland Schüle; Peter J. Wild
• Keywords: Tissue microarray; Hematology

Abstract Purpose The newly discovered histone methyltransferase KMT9 serves as an epigenetic regulator of carcinogenesis in various cancer entities. For the first time, we investigated presence KMT9α cholangiocarcinoma, association with histologic subtypes, and its impact on survival. Methods A tissue microarray cohort all CCA patients who underwent surgical resection curative intent between 08/2005 12/2021 at University Hospital Frankfurt was immunohistochemically analyzed antibody. overall survival, Kaplan–Meier curves Cox-regression analyses were performed. Results In total, 174 suitable for IHC analysis. Of patients, 35.1% ( n = 61) overexpressed KMT9α. Kaplan-Meier revealed a median OS 34.75 months (95% CI 20.23–49.27 months) positive comparison to 54.21 41.78–66.63 lacking overexpression p 0.004). Subtype analysis strong differences expression. Multivariate Cox regression identified independent risk factor shorter CCA. Conclusion This study demonstrates that marked subset exhibit These findings underscore prognostic significance reinforce potential therapeutic target, consistent role other types.